Litcius/Paper detail

How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

Ana P. Kiess, Joseph A. O’Donoghue, Carlos Uribe, Lisa Bodei, Robert F. Hobbs, Jacob Hesterman, Adam Kesner, George Sgouros, Tom Bäck, Manuel Bardiès, Alessandro Bartolini, Søren M. Bentzen, Peter Bernhardt, Ingrid Bloise, Lisa Bodei, Wesley E. Bolch, P. Brodin, Julia Brosch-Lenz, Jacek Capala, Carlo Chiesa, Patricia E. Cole, Marta Cremonesi, Emmanuel Deshayes, Yuni K. Dewaraja, Roberto Formento-Cavaier, Gerhard Glatting, Harwig Hennekes, Jacob Hesterman, Robert F. Hobbs, Vicki Jardine, Jessica Jensen, Adam Kesner, Ana P. Kiess, Mark Konijnenberg, Clemens Kratochwil, Phillip H. Kuo, Roberto Maass‐Moreno, Michael J. Morris, Quyen T. Nguyen, Joseph A. O’Donoghue, Stig Palm, Neeta Pandit‐Taskar, Laurens Raes, Hendrik Rathke, Babak Saboury, Nicola Salem, Lore Santoro, Oliver Sartor, Mike Sathekge, George Sgouros, Eileen Sneeden, Lidia Strigari, Scott T. Tagawa, Carlos Uribe, Amanda J. Walker, Wolfgang Weber, Fred Wilson, Tahir Yusufaly, Sabine Zitzmann-Kolbe

2024Journal of Clinical Oncology32 citationsDOI

Topics & Concepts

MedicineClinical trialMedical physicsOncologyIntensive care medicineInternal medicineRadiopharmaceutical Chemistry and ApplicationsLung Cancer Treatments and MutationsNeuroendocrine Tumor Research Advances
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design | Litcius